NDA 205858 · Gilead Sciences INC
Zydelig
Idelalisib · Oral · Kinase Inhibitor
NovelAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Jul 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jul 23, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
66
14 Phase 3, 4 recruiting
FAERS reports
7,040
6,806 serious, 1,612 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION Fatal and/or serious hepatotoxicity occurred in 16% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . Fatal and/or serious and severe diarrhea or colitis occurred in 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig as recommended [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] . Fatal and/or serious pneumonitis occurred in 4% of Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended [see...
What it is approved for
From the label in effect Sep 10, 2026.
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. Zydelig is a kinase inhibitor indicated for the treatment of patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. ( 1 ) Limitations of use: Zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas. ( 1 , 6.1 ) Zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas. ( 6.1 ) Limitations of Use Zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas. Zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas.
Mechanism: Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2014 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLabelSummary ReviewLetter
2 products under this application
- ZYDELIG · IDELALISIB 150MG · TABLET, ORAL · Prescription · TE AB
- ZYDELIG · IDELALISIB 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Idelalisib" as an intervention, any sponsor and status, largest first.
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01732926 · 475 participants · Start Jan 2, 2013 · Primary completion May 17, 2016
Drug: Idelalisib; Rituximab and 2 more · For: Indolent Non-Hodgkin's Lymphomas
Sites: Huntsville, Alabama; Chandler, Arizona; Bakersfield, California · 144 sites in all
- Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01569295 · 416 participants · Start Jun 15, 2012 · Primary completion Jun 10, 2019
Drug: Idelalisib; Rituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Huntsville, Alabama; Los Angeles, California; Palo Alto, California · 106 sites in all
- Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01980888 · 311 participants · Start Feb 5, 2014 · Primary completion May 30, 2016
Drug: Idelalisib; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Fullerton, California; La Jolla, California; Santa Maria, California · 91 sites in all
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT02970318 · 310 participants · Start Feb 2, 2017 · Primary completion Sep 3, 2021
Drug: Acalabrutinib (ACP-196); Rituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Chandler, Arizona; Oxnard, California; Athens, Georgia · 157 sites in all
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01732913 · 295 participants · Start Jan 16, 2013 · Primary completion May 18, 2016
Drug: Placebo; Rituximab and 1 more · For: Indolent Non-Hodgkin's Lymphomas
Sites: Huntsville, Alabama; Chandler, Arizona; Duarte, California · 103 sites in all
- Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01659021 · 261 participants · Start Dec 4, 2012 · Primary completion Aug 15, 2018
Drug: Idelalisib; Ofatumumab · For: Chronic Lymphocytic Leukemia
Sites: Duarte, California; Fresno, California; San Diego, California · 80 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06846671 · 250 participants (planned) · Start Apr 10, 2025 · Primary completion May 15, 2028
Drug: Tacabrutideg; Bendamustine and 3 more · For: CLL; Chronic Lymphocytic Leukemia; SLL
Sites: Jonesboro, Arkansas; Los Angeles, California; San Diego, California · 134 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression1,225
- death802
- diarrhoea771
- off label use573
- pneumonia437
- pyrexia375
- drug ineffective318
- fatigue301
- dehydration244
- neutropenia224
- dyspnoea220
- colitis203
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 4 |
| 2014 | 253 |
| 2015 | 1,404 |
| 2016 | 1,357 |
| 2017 | 1,226 |
| 2018 | 980 |
| 2019 | 586 |
| 2020 | 377 |
| 2021 | 257 |
| 2022 | 197 |
| 2023 | 182 |
| 2024 | 113 |
| 2025 | 94 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Apr 7, 2026
Zydelig, Tablet, 150 mg (NDC 61958-1702-1). Discontinuation in the manufacturing of the drug
To Be Discontinued · updated Apr 7, 2026
Zydelig, Tablet, 100 mg (NDC 61958-1701-1). Discontinuation in the manufacturing of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zydelig (Idelalisib)
2024 spending
$4.4M
Beneficiaries
57
325 claims
Per beneficiary
$76,958
$226.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,637,314 |
| 2021 | $20,337,088 |
| 2022 | $15,120,868 |
| 2023 | $8,060,775 |
| 2024 | $4,386,599 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Sharman JP, Munir T, Grosicki S, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P, Pluta A, Wach M, et al. · J Clin Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.
Sedlarikova L, Petrackova A, Papajik T, et al. · Front Oncol 2020 · Systematic Review
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK, Kahl BS, de Vos S, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Lampson BL, Kasar SN, Matos TR, et al. · Blood 2016 · Clinical Trial
- Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
von Tresckow J, Heyl N, Robrecht S, et al. · Ann Hematol 2023 · Multicenter Study, Clinical Trial
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.